Clinical Trials Logo
  1. Home
  2. Nonalcoholic Fatty Liver
  3. NCT03763877

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Nonalcoholic Fatty Liver Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Clinical Trial Summary

This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.

Clinical Trial Description

The study will be performed in patients with Nonalcoholic Fatty Liver Disease. The primary endpoint will be the assessment of the change in the percentage of liver fat mass (assessed by MRI-PDFF). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03763877
Study type Interventional
Source Poxel SA
Contact
Status Completed
Phase Phase 2
Start date March 29, 2019
Completion date August 10, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT04031729 - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Phase 1/Phase 2
Recruiting NCT03725631 - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD N/A
Active, not recruiting NCT05084404 - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease Phase 2
Completed NCT05081427 - Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
Recruiting NCT05430178 - Metabolic Pathology of Pediatric NAFLD N/A
Recruiting NCT04389593 - Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference
Active, not recruiting NCT05199948 - Weight, Energy, Lipids, and the Liver (WELL) Study N/A
Active, not recruiting NCT03696797 - Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Completed NCT05309642 - Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study N/A
Not yet recruiting NCT06335771 - Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity N/A
Completed NCT04828551 - Noninvasive Biomarkers of Metabolic Liver Disease 1.1 N/A
Recruiting NCT05792423 - Conditionally Increased Output (CIO) Enhanced Ultrasound System N/A
Recruiting NCT02815891 - A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Not yet recruiting NCT05908877 - Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Not yet recruiting NCT04887766 - Study on GS300 on NAFLD N/A
Completed NCT03986684 - Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Recruiting NCT05165706 - Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance N/A
Completed NCT04235205 - Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease Phase 2
Recruiting NCT05680233 - Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis Phase 1